KCS Wealth Advisory’s Biogen BIIB Stock Holding History

KCS Wealth Advisory’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2	Closed	-$466	–	175
2019 Q3	$466	Buy	+2	New	+$466	﹤0.01%	448

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

KCS Wealth Advisory's BIIB Position: Q4 2019 in Review

KCS Wealth Advisory sold out of Biogen (BIIB) in Q4 2019, closing a stake of 2 shares — an estimated $466 sold.

KCS Wealth Advisory first reported a position in BIIB in Q3 2019 and held it in 1 quarter. The position peaked at $466 in Q3 2019. 1,103 funds tracked by Wall St. Rank hold BIIB as of Q4 2019.

KCS Wealth Advisory reported no remaining Biogen position as of Q4 2019 after selling out during the quarter.
KCS Wealth Advisory sold 2 Biogen shares in Q4 2019, an estimated $466.
KCS Wealth Advisory first reported a position in Biogen in Q3 2019 and held it in 1 quarter.
KCS Wealth Advisory's Biogen position peaked at $466 in Q3 2019.
1,103 funds tracked by Wall St. Rank held Biogen as of Q4 2019.

Based on KCS Wealth Advisory's 13F filing for Q4 2019, filed 15 Jan 2020.